Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Director departure
Appointed director
CC transcript
Inv. presentation
Director comp.

Assertio Therapeutics, Inc (ASRT) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/22/2021 GN Assertio Holdings, Inc. to Report First Quarter 2021 Financial Results After the Close of Markets on Thursday, May 6, 2021
02/12/2021 GN Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $34.3 Million
02/12/2021 SC 13G/A Allianz Global Investors U.S. Holdings LLC reports a 0% stake in Assertio Therapeutics, Inc.
02/10/2021 GN Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering
02/05/2021 GN Assertio Holdings, Inc. Announces Pricing of $14 Million Registered Direct Offering
02/03/2021 GN Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates
12/29/2020 GN Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market
12/15/2020 GN Assertio Announces Restructuring Plan and Leadership Changes
11/06/2020 GN Assertio Reports Third Quarter 2020 Financial Results
08/07/2020 GN Assertio Reports Second Quarter 2020 Financial Results
07/20/2020 GN Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020
06/18/2020 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
05/22/2020 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: "Agreement and Plan of Merger, by and among Assertio Therapeutics, Inc., Assertio Holdings, Inc., and Alligator Merger Sub, Inc",
"Certificate of Merger",
"Amended and Restated By-laws of Assertio Therapeutics, Inc."
05/19/2020 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
05/18/2020 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/11/2020 10-Q Quarterly Report for the period ended March 31, 2020
05/11/2020 8-K Quarterly results
05/11/2020 425 Form 425 - Prospectuses and communications, business combinations:
04/24/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
04/20/2020 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2020 GN Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus
04/08/2020 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
04/08/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024"
03/26/2020 SC 13D DEPOMED INC reports a 51% stake in Zyla Life Sciences
03/25/2020 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
03/17/2020 GN Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies – WLTW, TTPH, ASRT, MEET
03/17/2020 8-K Asset disposition
Docs: "Agreement and Plan of Merger by and among Assertio Therapeutics, Inc., Alligator Zebra Holdings, Inc., Alligator Merger Sub, Inc., Zebra Merger Sub, Inc. and Zyla Life Sciences",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Transition Agreement by and among Assertio Therapeutics, Inc. and Arthur Higgins",
"Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd Smith to be Named President and CEO of Combined Company",
"Employee FAQs",
"Investor Presentation"
03/17/2020 425 Form 425 - Prospectuses and communications, business combinations:
03/16/2020 GN Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products
03/11/2020 SC TO-I Form SC TO-I - Tender offer statement by Issuer:
03/11/2020 8-K Quarterly results
03/10/2020 10-K Annual Report for the period ended December 31, 2019
03/09/2020 8-K Quarterly results
03/09/2020 GN Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy